Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Iacoboni G, Navarro V, Martín-López AÁ, Rejeski K, Kwon M, Jalowiec KA, Amat P, Reguera-Ortega JL, Gallur L, Blumenberg V, Gutiérrez-Herrero S, Roddie C, Benzaquén A, Delgado-Serrano J, Sánchez-Salinas MA, Bailén R, Carpio C, López-Corral L, Hernani R, Bastos M, O'Reilly M, Martín-Martín L, Subklewe M, Barba P. Iacoboni G, et al. Among authors: barba p. J Clin Oncol. 2024 Jan 10;42(2):205-217. doi: 10.1200/JCO.23.01097. Epub 2023 Oct 24. J Clin Oncol. 2024. PMID: 37874957
Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies.
Barba P, Valcárcel D, Pérez-Simón JA, Fernández-Avilés F, Piñana JL, Martino R, López-Anglada L, Rovira M, Garcia-Cadenas I, Novelli S, Carreras E, López Corral L, Sierra J. Barba P, et al. Biol Blood Marrow Transplant. 2013 Apr;19(4):597-601. doi: 10.1016/j.bbmt.2012.12.018. Epub 2013 Jan 8. Biol Blood Marrow Transplant. 2013. PMID: 23305680 Free article.
GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.
Parody R, Lopez-Corral L, Godino OL, Cadenas IG, Martinez AP, Vazquez L, Martino R, Martinez C, Solano C, Barba P, Valcarcel D, Caballero-Velazquez T, Marquez-Malaver FJ, Sierra J, Caballero D, Perez-Simón JA. Parody R, et al. Among authors: barba p. Bone Marrow Transplant. 2015 Jan;50(1):121-6. doi: 10.1038/bmt.2014.220. Epub 2014 Oct 13. Bone Marrow Transplant. 2015. PMID: 25310306 Clinical Trial.
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .
Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, Valcárcel D, Solano C, López-Corral L, Sierra J, Perales MA. Barba P, et al. Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2. Biol Blood Marrow Transplant. 2018. PMID: 29305194 Free PMC article.
Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy.
Nieto JC, Roldán E, Jiménez I, Fox L, Carabia J, Ortí G, Puigdefàbregas L, Gallur L, Iacoboni G, Raheja P, Pérez A, Bobillo S, Salamero O, Palacio C, Valcárcel D, Crespo M, Bosch F, Barba P. Nieto JC, et al. Among authors: barba p. Leukemia. 2020 Dec;34(12):3420-3425. doi: 10.1038/s41375-020-0851-8. Epub 2020 May 11. Leukemia. 2020. PMID: 32393842
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper.
Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Díaz de Heredia C, Fortuny-Guasch C, García-Cadenas I, García-Vidal C, González-Vicent M, Hernani R, Kwon M, Machado M, Martínez-Gómez X, Maldonado VO, Pla CP, Piñana JL, Pomar V, Reguera-Ortega JL, Salavert M, Soler-Palacín P, Vázquez-López L, Barba P, Ruiz-Camps I. Los-Arcos I, et al. Among authors: barba p. Infection. 2021 Apr;49(2):215-231. doi: 10.1007/s15010-020-01521-5. Epub 2020 Sep 26. Infection. 2021. PMID: 32979154 Free PMC article. Review.
Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro J, Roldán E, Piñana JL, Barba P, Chorão P, Quintero A, Hernani R, Ortí G, Lorenzo JI, Balaguer-Roselló A, Salamero O, Fox L, Solves P, Gómez I, Guerreiro M, Hernández Boluda JC, Sanz G, Solano C, Sanz MÁ, Valcárcel D, Sanz J. Montoro J, et al. Among authors: barba p. Eur J Haematol. 2021 Jan;106(1):114-125. doi: 10.1111/ejh.13529. Epub 2020 Oct 18. Eur J Haematol. 2021. PMID: 33025625
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Carpio C, Iacoboni G, Villacampa G, Catalá E, Bobillo S, Pérez A, Jiménez M, Segura L, Olivé M, Farriols A, Abrisqueta P, Valcárcel D, Carreras MJ, Bosch F, Barba P. Carpio C, et al. Among authors: barba p. Leuk Lymphoma. 2021 Sep;62(9):2288-2291. doi: 10.1080/10428194.2021.1913141. Epub 2021 Apr 24. Leuk Lymphoma. 2021. PMID: 33899648 No abstract available.
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martin Garcia-Sancho A, Kwon M, Reguera-Ortega JL, Barba P; GETH, GELTAMO Spanish Groups. Iacoboni G, et al. Among authors: barba p. Cancer Med. 2021 May;10(10):3214-3223. doi: 10.1002/cam4.3881. Epub 2021 May 1. Cancer Med. 2021. PMID: 33932100 Free PMC article.
282 results